Background: Cladribine tablets for the treatment of relapsing multiple sclerosis (RMS) are administered in two pulsed treatment courses in two consecutive years, totalling a maximum of 20 treatment days. Here we present data collected shortly after the launch of cladribine tablets, focusing on the patient's perspective. The objective was to investigate patients' perceived effectiveness, tolerability, and convenience, as well as global satisfaction of and with cladribine tablets., Methods: CLEVER was a non-interventional multicentre study conducted in Germany from 12/2017 to 7/2020. Adult patients with RMS initiating therapy with cladribine tablets were included. Observation time per patient was 24 weeks, comprising 3 visits (baseline, week 4 and 24). The primary endpoint was overall treatment satisfaction at week 24, assessed by the Treatment Satisfaction Questionnaire for Medication 14 items (TSQM 1.4). Subgroup analyses included stratification by prior treatment., Results: In total, 491 patients (69.2 % female; mean (±SD) age 40.3 (±11.5) years, 85.1 % pre-treated, median EDSS 2.5) initiated therapy with cladribine tablets and were included in the analysis. At week 24, the mean (±SD) global TSQM satisfaction score was 75.6 (±19.0). For patients switching from either injectables or oral medication, the change in therapy satisfaction from baseline to week 24 was positive in all TSQM domains with clinically meaningful effect sizes in the global satisfaction and side effects domains. Most patients (85.5 %) remained relapse-free over 24 weeks. Out of 491 patients, 187 (38.1 %) experienced at least one adverse event and 8 patients (1.6 %) one serious adverse event., Conclusion: Treatment satisfaction with cladribine tablets was high. The switch from prior injectables or oral medication translated into increased treatment satisfaction at week 24 with clinically meaningful effects in the global satisfaction and side effects domains. Effectiveness and safety were consistent with results from clinical studies., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Tjalf Ziemssen reports financial support was provided by Merck Healthcare Germany GmbH. Tjalf Ziemssen reports a relationship with Almirall that includes: consulting or advisory and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Bayer Pharma that includes: consulting or advisory and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Biogen that includes: consulting or advisory, funding grants, and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Celgene that includes: consulting or advisory and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Sanofi-Genzyme that includes: consulting or advisory, funding grants, and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Merck that includes: consulting or advisory and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Novartis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Roche that includes: consulting or advisory and speaking and lecture fees. Tjalf Ziemssen reports a relationship with Teva that includes: consulting or advisory, funding grants, and speaking and lecture fees. Anita Posevitz-Fejfár reports a relationship with Merck Healthcare Germany GmbH that includes: employment. Anita Chudecka reports a relationship with Cytel Inc that includes: employment. Lukas Cepek reports a relationship with Almirall that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Bayer that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Biogen Idec that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with BMS that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Celgene that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Mylan that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Genzyme -Sanofi that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Merck that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Novartis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Teva that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Roche that includes: consulting or advisory, funding grants, and speaking and lecture fees. Lukas Cepek reports a relationship with Zambon that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Merck that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Biogen that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Novartis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Sanofi that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Genzyme that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Sanofi Aventis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Roche that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with UCB that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Destin that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Health HERZ Economics Research Zentrum that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Hexal that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Hormosan that includes: consulting or advisory, funding grants, and speaking and lecture fees. Gerd Reifschneider reports a relationship with Med Day that includes: consulting or advisory, funding grants, and speaking and lecture fees. Christoph Grothe reports a relationship with Biogen that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Merck that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Novartis that includes: consulting or advisory, funding grants, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Sanofi that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Roche that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Boehringer Ingelheim that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Christoph Grothe reports a relationship with Teva that includes: consulting or advisory, speaking and lecture fees, and travel reimbursement. Joachim Richter reports a relationship with Merck Healthcare Germany GmbH that includes: employment. Torsten Wagner reports a relationship with Merck Healthcare Germany GmbH that includes: employment. Beate Müller reports a relationship with Merck Healthcare Germany GmbH that includes: employment. Iris-Katharina Penner reports a relationship with Adamas Pharma that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Almirall that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Bayer Pharma that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Biogen that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Celgene that includes: consulting or advisory, funding grants, and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Desitin that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Sanofi-Genzyme that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Janssen that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Merck Healthcare Germany GmbH that includes: consulting or advisory and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Novartis that includes: consulting or advisory, funding grants, and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Roche that includes: consulting or advisory, funding grants, and speaking and lecture fees. Iris-Katharina Penner reports a relationship with Teva that includes: consulting or advisory, funding grants, and speaking and lecture fees. Iris-Katharina Penner reports a relationship with German MS Society that includes: funding grants., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)